Risperidone in the treatment of psychotic depression

被引:32
作者
Goto, Makiko [1 ]
Yoshimura, Reiji [1 ]
Kakihara, Shingo [1 ]
Shinkai, Koji [1 ]
Yamada, Yasuhisa [1 ]
Kaji, Kyoko [1 ]
Ueda, Nobuhisa [1 ]
Nakamura, Jun [1 ]
机构
[1] Univ Occupat & Environm Hlth, Dept Psychiat, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan
关键词
HVA; MHPG; paroxetine; psychotic depression; risperidone;
D O I
10.1016/j.pnpbp.2006.01.016
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In the preset study, the authors investigated that effects of the antipsychotic drug risperidone on psychotic depression and examined the mechanism of risperidone to ameliorate psychotic depression. Fifteen patients met the DSM-IV criteria for major depressive disorder with psychotic features and the remaining five patients met those for bipolar I disorder (most recent episode depressed) with psychotic features (M/F: 8/12, age: 54 +/- 18). All patients were evaluated regarding their clinical improvement using the Hamilton Rating Scale for Depression (Ham-D), and Positive and Negative Syndrome Scale (PANSS). In addition, plasma concentrations of HVA and MHPG were analyzed by HPLC. Patients with a 50% or more improvement in Ham-D score were defined as responders. Three were prescribed risperidone alone, and the other 17 were administered risperidone as an addition to preexisting antidepressants or mood stabilizers. The preexisting antidepressants or mood stabilizers were as follows: paroxetine (6), lithium (3), valproic acid (3), clomipramine (2), fluvoxamine (1), amitriptyline (1), amoxapine (1). The average dose of risperidone was 1.8 +/- 0.5 mg/day. Eleven of twenty patients (55%) turned out to be responders 4 weeks after initiation of risperidone administration. No differences were observed between responders and nonresponders with respect to age, sex, Ham-D score before risperidone treatment, dose and plasma level of risperidone or its active metabolite, 9-hydroxyrisperidone. Plasma HVA levels before risperidone administration in responders were significantly higher than those in nonresponders. In addition, a significant correlation was observed between changes in plasma HVA level and the percentage improvement on Ham-D score. These results indicate that treatment with risperidone is effective to ameliorate psychotic depression, and the influence of risperidone on dopaminergic activity is associated with its efficacy. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:701 / 707
页数:7
相关论文
共 48 条
[31]  
ROOSE SP, 1988, DEPRESSION MANIA, P76
[32]   Olanzapine response in psychotic depression [J].
Rothschild, AJ ;
Bates, KS ;
Boehringer, KL ;
Syed, A .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (02) :116-118
[33]   Challenges in the treatment of depression with psychotic features [J].
Rothschild, AJ .
BIOLOGICAL PSYCHIATRY, 2003, 53 (08) :680-690
[34]  
ROTHSCHILD AJ, 1993, BIOL PSYCHIAT, V34, P392
[35]  
SCHATZBERG AF, 1992, AM J PSYCHIAT, V149, P733
[36]   Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment [J].
Shinkai, K ;
Yoshimura, R ;
Ueda, N ;
Okamoto, K ;
Nakamura, J .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2004, 24 (01) :11-17
[37]   Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine [J].
Spina, E ;
Avenoso, A ;
Facciolà, G ;
Scordo, MG ;
Ancione, M ;
Madia, A .
THERAPEUTIC DRUG MONITORING, 2001, 23 (03) :223-227
[38]   Tranylcypromine plus risperidone for treatment-refractory major depression [J].
Stoll, AL ;
Haura, G .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (04) :495-496
[39]  
SWEENEY D, 1978, LANCET, V2, P100
[40]   Augmentation of milnacipran by risperidone in treatment for major depression [J].
Tani, K ;
Takei, N ;
Kawai, M ;
Suzuki, K ;
Sekine, Y ;
Toyoda, T ;
Minabe, Y ;
Mori, N .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 (01) :55-58